Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer.

Aurelius Omlin,Richard Cathomas,Gunhild von Amsberg,Christoph Reuter,Susan Feyerabend,Wolfgang Loidl,Martin Boegemann,Anja Lorch,Axel Heidenreich,Igor Tsaur,Julian Larcher-Senn,Stefan Buck,Ron H J Mathijssen,Ulrich Jaehde,Silke Gillessen,Markus Joerger

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览18

暂无评分

摘要

Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要